Considering the expression patterns of these genes across different HCC cell subpopulations, our findings suggest that TRIB3 and NQO1 hold promise as potential indicators for assessing the outcomes of ICB therapy. This evidence concerns the gene TRIB3 and hepatocellular carcinoma.